Therefore, this study aims to explore the effects of miR-138 targeting SEMA4C in BC cells on epithelial-mesenchymal transition and invasion, to verify the potential of miR-138 as a clinical BC tumor marker, and to provide molecular targeted therapy for breast cancer New reference path. The gene discussed is SEMA4C; the disease is neoplasm.